Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics, pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Meeting the demand
for new antibiotics


A new class of antibiotics

Nabriva is focused on the development of pleuromutilins, a new class of antibiotics addressing a significant medical need.


Nabriva's lead product lefamulin

Lefamulin (BC‑3781) addresses significant medical needs, differentiated from all other agents and is about to enter Phase 3 studies.